Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak, Takashi Nakano, Jan van Meerbeeck, Sanjay Popat, Nicholas J. Vogelzang, Federica Grosso, Rasha Aboelhassan, Marko Jakopovic, Giovanni L. Ceresoli, Paul Taylor, Francisco Orlandi, Dean A. Fennell, Silvia Novello, Arnaud Scherpereel, Kozo Kuribayashi, Susana Cedres, Jens Benn Sørensen, Nick PavlakisMartin Reck, Derek Velema, Ute von Wangenheim, Miyoung Kim, José Barrueco, Anne S. Tsao

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Fingerprint

Dive into the research topics of 'Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences